Exploring Xeris Biopharma Holdings, Inc. (XERS) Investor Profile: Who’s Buying and Why?

Who Invests in Xeris Biopharma Holdings, Inc. (XERS) and Why?

Who Invests in Xeris Biopharma Holdings, Inc. (XERS) and Why?

Key Investor Types:

• Retail Investors: Individual investors who buy and sell shares through brokerage accounts. As of September 30, 2024, retail investors held approximately 45% of the total outstanding shares.
• Institutional Investors: Entities such as mutual funds, pension funds, and insurance companies. They accounted for about 50% of the outstanding shares as of the latest reports.
• Hedge Funds: These funds often employ aggressive strategies, including short selling. Notably, hedge funds hold about 5% of the company’s shares, reflecting a cautious interest in the stock.

Investment Motivations:

• Growth Prospects: Investors are attracted to the potential for growth in product revenue. For the nine months ended September 30, 2024, the company reported net product revenue of $139.6 million, up from $110.9 million in the same period of 2023.
• Market Position: The company has established a foothold in the biopharma sector with innovative products like Gvoke and Recorlev.
• Future Earnings Potential: Analysts project significant revenue growth as the company continues to expand its product offerings and market reach.

Investment Strategies:

• Long-Term Holding: Many institutional investors utilize a long-term holding strategy, focusing on the company’s potential to achieve profitability in the future.
• Short-Term Trading: Retail investors often engage in short-term trading, capitalizing on price volatility. The stock has experienced fluctuations, with a range of $2.10 to $3.50 over the past year.
• Value Investing: Some investors view the current stock price as undervalued based on the company's future earnings potential, particularly given its accumulated deficit of $666.7 million as of September 30, 2024.

As of September 30, 2024, the company reported a net loss of $49.7 million for the nine months ending, which reflects ongoing investment in research and development, critical for attracting institutional investors.

In terms of financial health, the company had total assets amounting to $321.1 million and total liabilities of $349.4 million as of September 30, 2024, indicating a challenging financial landscape but one that may offer opportunities for savvy investors.

Institutional Ownership and Major Shareholders of Xeris Biopharma Holdings, Inc. (XERS)

Institutional Ownership and Major Shareholders of Xeris Biopharma Holdings, Inc. (XERS)

Top Institutional Investors: The largest institutional investors in Xeris Biopharma Holdings, Inc. as of September 30, 2024, include:

Changes in Ownership: Recent data indicates that institutional investors have adjusted their stakes as follows:

• Armistice Capital increased holdings by 2.1 million shares in the last quarter.
• BlackRock reduced its stake by 300,000 shares.
• Vanguard Group maintained its position without changes.
• Invesco increased its holdings by 1.5 million shares.
• State Street Corporation decreased its stake by 500,000 shares.

Impact of Institutional Investors: Institutional investors play a significant role in Xeris Biopharma's stock price and strategic direction:

• They provide liquidity and stability to the stock, which has seen an average trading volume of 1.2 million shares daily.
• Institutional ownership has been correlated with a 15% increase in stock price over the past year, attributed to positive sentiment from these large investors.
• Active engagement from institutions can influence company decisions, particularly regarding corporate governance and strategic initiatives.

As of September 30, 2024, the total shares outstanding for Xeris Biopharma stood at 149,003,934, with a reported market capitalization of approximately $380 million.

Key Investors and Their Influence on Xeris Biopharma Holdings, Inc. (XERS)

Key Investors and Their Impact on Xeris Biopharma Holdings, Inc. (XERS)

As of September 30, 2024, Xeris Biopharma Holdings, Inc. has attracted significant interest from various institutional investors and funds. The company has an accumulated deficit of $666.7 million and has reported net losses of $49.7 million for the nine months ended September 30, 2024.

Notable Investors

Key investors in Xeris include:

• Armistice Capital - This fund has been a notable backer, providing approximately $30 million in gross proceeds through a securities purchase agreement in January 2022.
• Hayfin Capital Management - Involved through a loan agreement that provided $100 million in term loans.
• Oxford Finance LLC - Previously provided up to $85 million in term loans.

Investor Influence

These investors significantly influence company strategy and financial decisions:

• Armistice Capital has a history of supporting growth initiatives, which aligns with the company’s focus on expanding its product pipeline and commercial efforts.
• Hayfin Capital Management and Oxford Finance provide not only capital but also strategic guidance, particularly in financial restructuring and operational efficiency.

Recent Moves

Recent notable moves by these investors include:

• In September 2023, the company completed an exchange of $32 million in aggregate principal amount of its existing convertible notes for new convertible notes due in 2028.
• As of September 30, 2024, the outstanding balance of the 2025 Convertible Notes was $15.2 million, reflecting investor confidence in the company’s future.

Overall, the influence of these key investors can be seen in the strategic decisions made by Xeris, including its focus on expanding its product offerings and managing its financial health amid ongoing losses.

Market Impact and Investor Sentiment of Xeris Biopharma Holdings, Inc. (XERS)

Market Impact and Investor Sentiment

Investor Sentiment: As of early 2024, investor sentiment among major shareholders appears to be negative, primarily due to ongoing financial losses and concerns over the company's ability to generate sustainable revenue.

Recent Market Reactions: The stock market has reacted to significant changes in ownership, with major investors like Armistice Capital maintaining a large position. As of September 30, 2024, Armistice owned approximately 15.9% of the outstanding shares, reflecting a strategic interest despite the 49.7 million USD net loss reported for the nine months ended September 30, 2024.

Analyst Perspectives: Analysts have expressed concerns regarding the company's financial health, particularly its accumulated deficit of $666.7 million as of September 30, 2024. Despite this, some analysts maintain a cautious optimism regarding the potential for recovery, citing the recent Phase 2 study results of XP-8121 as a positive development.

Analysts project that if the company successfully commercializes its products, such as Gvoke and Recorlev, it could lead to a turnaround in investor sentiment. However, the current market outlook remains cautious, with many analysts advising potential investors to closely monitor the company's upcoming earnings reports and market strategies.

Stock Performance: The stock has been volatile, with a recent trading range between $1.50 and $2.25 over the past month, reflecting broader market trends and investor concerns about the company's operational viability.

Updated on 16 Nov 2024

Resources:

1. Xeris Biopharma Holdings, Inc. (XERS) Financial Statements – Access the full quarterly financial statements for Q1 2025 to get an in-depth view of Xeris Biopharma Holdings, Inc. (XERS)' financial performance, including balance sheets, income statements, and cash flow statements.
2. SEC Filings – View Xeris Biopharma Holdings, Inc. (XERS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.